Nasdaq confirms Aptose regained compliance with Listing Rule 5635(d) after warrant amendment

Aptose Biosciences Inc.

Aptose and Hanmi amended warrant to cap exercise at 19.99% of outstanding shares without shareholder approval.
Hanmi received 2,339,181 warrants at $1.71/share, exercisable for 5 years from issuance.
Nasdaq Staff determined compliance with Rule 5635(d) regained; matter closed.
Original violation stemmed from Jan 25, 2024 Hanmi transaction that issued >20% shares at a discount.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Aptose Biosciences Inc. amended Amended and Restated Warrant to Purchase Common Shares with Hanmi Pharmaceutical Co., Ltd. valued at 2,339,181 warrants at $1.71 per share (effective 2024-04-24).

Action: amendment
Agreement: equity purchase
Counterparty: Hanmi Pharmaceutical Co., Ltd.
Value: 2,339,181 warrants at $1.71 per share
Effective: 2024-04-24

Exact text from the filing

On April 24, 2024, Aptose Biosciences Inc. (the “ Company ”) entered into an Amended and Restated Warrant to Purchase Common Shares (the “ Amended Warrant Agreement ”) with Hanmi Pharmaceutical Co., Ltd. (“ Hanmi ”) in order to comply with Listing Rule 5635 of The Nasdaq Stock Market LLC (“ Nasdaq ”).

View on SEC.gov

246 material agreements filed in the last 30 days. Browse all material agreements →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002270

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.